Alphatec (NASDAQ:ATEC) Reaches New 1-Year High – Should You Buy?

Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) reached a new 52-week high during mid-day trading on Thursday . The stock traded as high as $21.16 and last traded at $20.75, with a volume of 3682193 shares changing hands. The stock had previously closed at $20.72.

Analyst Ratings Changes

ATEC has been the topic of a number of research analyst reports. HC Wainwright upped their price target on shares of Alphatec from $20.00 to $24.00 and gave the company a “buy” rating in a research report on Friday, October 31st. Wall Street Zen upgraded Alphatec from a “hold” rating to a “buy” rating in a research report on Saturday, October 18th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Alphatec in a research note on Tuesday. Stifel Nicolaus initiated coverage on Alphatec in a research note on Tuesday, October 28th. They issued a “buy” rating and a $20.00 price target on the stock. Finally, Needham & Company LLC raised their price objective on shares of Alphatec from $16.00 to $22.00 and gave the stock a “buy” rating in a research report on Friday, October 31st. Nine research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $22.00.

Alphatec Trading Up 0.1%

The business has a 50 day moving average of $15.92 and a two-hundred day moving average of $13.78. The firm has a market capitalization of $3.08 billion, a price-to-earnings ratio of -18.36 and a beta of 1.17. The company has a debt-to-equity ratio of 23.22, a quick ratio of 1.77 and a current ratio of 2.88.

Alphatec (NASDAQ:ATEC) last announced its quarterly earnings data on Thursday, October 30th. The medical technology company reported $0.03 EPS for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.09. The firm had revenue of $196.50 million during the quarter, compared to analyst estimates of $182.78 million. During the same period last year, the business posted ($0.28) EPS. The company’s revenue was up 30.4% on a year-over-year basis. Alphatec has set its FY 2025 guidance at EPS. Equities analysts predict that Alphatec Holdings, Inc. will post -1.08 EPS for the current year.

Insider Activity

In other news, EVP Craig E. Hunsaker sold 100,000 shares of the business’s stock in a transaction dated Friday, October 31st. The shares were sold at an average price of $19.95, for a total transaction of $1,995,000.00. Following the completion of the sale, the executive vice president directly owned 1,289,142 shares of the company’s stock, valued at $25,718,382.90. The trade was a 7.20% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Jeffrey P. Rydin sold 200,000 shares of the company’s stock in a transaction dated Monday, November 3rd. The stock was sold at an average price of $19.32, for a total transaction of $3,864,000.00. Following the completion of the sale, the director owned 385,441 shares in the company, valued at $7,446,720.12. This represents a 34.16% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 1,078,823 shares of company stock valued at $18,215,195. 20.90% of the stock is currently owned by insiders.

Institutional Trading of Alphatec

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ATEC. Aster Capital Management DIFC Ltd purchased a new stake in shares of Alphatec in the third quarter worth approximately $34,000. Osterweis Capital Management Inc. bought a new stake in Alphatec during the second quarter worth $37,000. Larson Financial Group LLC purchased a new stake in Alphatec in the 1st quarter valued at $54,000. Nisa Investment Advisors LLC lifted its stake in Alphatec by 22.4% during the 2nd quarter. Nisa Investment Advisors LLC now owns 5,714 shares of the medical technology company’s stock valued at $63,000 after acquiring an additional 1,045 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. bought a new position in Alphatec during the 3rd quarter valued at $73,000. 66.35% of the stock is owned by institutional investors.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.